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Abstract
In this study, we examined the Ca2+-permeable Piezo1 channel, a newly identified
mechanosensing ion channel, in human dental pulp-derived mesenchymal stem cells
(MSCs) and hypothesized that activation of the Piezo1 channel regulatesMSCmigration
via inducing ATP release and activation of the P2 receptor purinergic signaling. The
Piezo1 mRNA and protein were readily detected in hDP-MSCs from multiple donors
and, consistently, brief exposure to Yoda1, the Piezo1 channel-specific activator, ele-
vated intracellular Ca2+ concentration. Yoda1-induced Ca2+ response was inhibited by
ruthenium red or GsMTx4, two Piezo1 channel inhibitors, and also by Piezo1-specific
siRNA. Brief exposure to Yoda1 also induced ATP release. Persistent exposure to Yoda1
stimulated MSC migration, which was suppressed by Piezo1-specific siRNA, and also
prevented by apyrase, an ATP scavenger, or PPADS, a P2 generic antagonist. Further-
more, stimulation ofMSCmigration induced by Yoda1 aswell as ATPwas suppressed by
PF431396, a PYK2 kinase inhibitor, or U0126, an inhibitor of themitogen-activated pro-
tein kinase MEK/ERK signaling pathway. Collectively, these results suggest that activa-
tion of the Piezo1 channel stimulates MSC migration via inducing ATP release and
subsequent activation of the P2 receptor purinergic signaling and downstream PYK2
and MEK/ERK signaling pathways, thus revealing novel insights into the molecular and
signaling mechanisms regulating MSC migration. Such findings provide useful informa-
tion for evolving a full understanding of MSC migration and homing and developing
strategies to improveMSC-based translational applications.
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1 | INTRODUCTION
Mesenchymal stem cells (MSCs), which have been isolated from bone
marrow, umbilical cord, dental pulp, and a diversity of other tissues,
have the ability of differentiating into tissue-specific lineages.1-3 An
increasing number of studies have demonstrated promising applica-
tions of MSCs in regenerative medicine and tissue engineering to
repair and regenerate damaged or lost tissues due to diseases and
Received: 9 November 2018 Accepted: 1 September 2019
DOI: 10.1002/stem.3114
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
©2019 The Authors. STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press 2019
410 STEM CELLS. 2020;38:410–421.wileyonlinelibrary.com/journal/stem
traumatic injuries4-21 and, nonetheless, translational uses of MSCs
remain inefficacious, in part due to their limited capability of migrating
and homing.3,22-26 Thus, gaining insights into the mechanisms regulat-
ing MSC migration can provide useful information for developing
novel strategies to prepare MSCs for clinical applications and improve
the efficacy of MSC-based therapies as well as evolving a better
understanding of the contentious MSC biology.27,28 A multiplicity of
extracellular signaling molecules and cell surface receptors for them
and coupled intrinsic signaling mechanisms have been shown to regu-
late cell migration.29-32 ATP represents one such signaling molecule
that selectively activates the P2 purinergic receptor family, which is
composed of ligand-gated ion channel P2X receptors and G-protein-
coupled P2Y receptors.32,33 ATP-induced purinergic signaling has
been well documented in MSCs from different species and tissues34
and, furthermore, has been demonstrated to play an important role in
regulating MSC proliferation35,36 and differentiation37,38 as well as
migration and homing.39,40
Increasing evidence indicates that various physical and chemical
stimuli can stimulate ATP release from MSCs.35,38 MSCs are
mechanosensitive,41,42 and mechanical forces can induce ATP release,
but the mechanisms for mechanical induction of ATP release from
MSCs remain poorly understood.32 The Ca2+-permeable Piezo1 chan-
nel is a newly discovered mechanosensing mechanism in many types
of cells.43-55 Furthermore, recent studies have reported that mechani-
cal or chemical activation of the Piezo1 channel induces ATP release
from endothelial cells,48 urothelial cells,54 and red blood cells.55 There
is also compelling evidence to support a critical role for the Piezo1
channel in regulating cell migration in endothelial cells,56 breast cancer
cells,57 gastric cancer cells,50,58 and small lung cancer cells.59 Recent
studies have also shown the expression of the Piezo1 channel in
human bone marrow-derived MSCs (BM-MSCs)60 and rat dental pulp-
derived stem cells (DP-MSCs).61 Therefore, it is attractive to hypothe-
size that the Piezo1 channel regulates MSC migration via inducing
ATP release and subsequent activation of the P2 receptor purinergic
signaling.32,40
Recent studies have reported that the mitogen-activated protein
kinase/extracellular signal-regulated kinase (MEK/ERK) or ERK is criti-
cally engaged as a downstream signaling pathway in mediating
acetylcholine-induced rat BM-MSC migration62 and interleukin-1β-
induced human umbilical cord-derived MSC (UC-MSC) migration.63 It
has been proposed that the Piezo1 channel mediates ultrasound-induced
activation of the MEK/ERK signaling pathway in rat DP-MSCs.61 The
proline-rich tyrosine kinase 2 (PYK2) is well-known as a signaling mole-
cule downstream of intracellular Ca2+ and plays a critical role in mediating
Ca2+-dependent induction of the MEK/ERK pathway in monocyte,
microglial, and neuronal cells.64-70 There is evidence for involvement of
PYK2 in cancer cell migration,70 but it is unclear whether PYK2 plays a
role in the regulation of MSC migration.
Therefore, in this study, we examined the expression of the
Piezo1 channel in human dental pulp-derived MSCs (hDP-MSCs) and
its role in the regulation of cell migration. Particularly, we investigated
the hypothesis of activation of the Piezo1 channel as a mechanism
regulating hDP-MSC migration via inducing ATP release and
subsequent activation of the P2 receptor purinergic signaling. We also
explored the role of PYK2 and MEK/ERK as the downstream signaling
pathways in mediating hDP-MSC migration. Our results show func-
tional expression of the Piezo1 channel in hDP-MSCs and its impor-
tant role in stimulating cell migration, and provide further evidence to
support that activation of the Piezo1 channel stimulates cell migration
via inducing ATP release and subsequent activation of the P2 receptor
purinergic signaling and downstream PYK2 and MEK/ERK signaling
pathways. These novel findings provide a better understanding of the
molecular and signaling mechanisms regulating MSC migration and
useful information for the development of strategies to improve appli-
cations of MSCs in regenerative medicine and tissue engineering.
2 | MATERIALS AND METHODS
2.1 | Chemicals and media
All chemicals or reagentswere obtained fromSigma-Aldrich, unless spec-
ified otherwise. Yoda1, PF431396, GsMTx4, and PPADS were from
Tocris. U0126 and ionomycin were from Cayman Chemical. Ruthenium
red (RR) was from Merck. Ca2+/Mg2+-free phosphate-buffered saline
(PBS), Dulbecco's modified Eagle's medium (DMEM), GlutaMAX-I, OPTI-
MEM, fetal bovine serum (FBS), penicillin-streptomycin, trypsin-EDTA,
Fura-2/acetoxymethyl (Fura-2/AM), and pluronic acid F-127 were from
Invitrogen.
2.2 | Cell culture
Human DP-MSCs were isolated from the molar teeth from two
female donors of 9 and 32 years old and two male donors of 22 and
20 years old (9F, 32F, 22M, and 20M in abbreviation) and character-
ized for the expression of positive and negative cell surface MSC
Significance statement
Mesenchymal stem cells (MSCs) release ATP as an extracellular
signaling molecule in response to mechanical and diverse other
stimuli, but the underlying mechanisms remain largely elusive.
This study shows the expression of the Ca2+-permeable Piezo1
channel, a newly discovered mechanosensing mechanism, in
human dental pulp-derived MSCs and its important role in the
regulation of MSC migration. It further demonstrates that acti-
vation of the Piezo1 channel stimulates MSC migration via
inducing ATP release and subsequent activation of P2 receptor
purinergic signaling. This study thus provides novel insights into
the mechanisms regulating MSCmigration. Such information is
useful for gaining a better understanding ofMSCmigration and
designing strategies to improve applications of MSCs in tissue
engineering and regenerativemedicine.
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markers and in vitro differentiation potentials as described in our pre-
vious study.40 Cells were maintained in DMEM supplemented with
GlutaMAX-I, 10% FBS and 100 units/mL penicillin and 100 μg/mL
streptomycin at 37C and 5% CO2 in a tissue culture incubator. Cells,
when reaching 80-90% confluency, were passaged and, when cells
were settled down during incubation for 24 hours, the growth
medium was replaced with fresh growth medium. Cells of 4-6 pas-
sages were used in this study.
2.3 | RT-qPCR analysis
Cells were plated at 80 000 per well in six-well plates. Cells were col-
lected when reaching 80-90% confluency, and total RNA was extracted
using a RNAqueous-Micro kit and treated with a TURBO DNA-free kit
(both from Invitrogen). The RNA concentration and purity were deter-
mined using a Nanodrop 2000c spectrophotometer (Thermo Scientific),
and 0.6 μg RNA was reverse-transcribed into cDNA in a 20-μL reaction
volume using a High Capacity RNA-to-cDNA kit (Applied Biosystems)
and a Mastercycler Gradient PCR machine (Eppendorf) at 37C for
60 minutes. The reverse transcription (RT) was stopped at 95C for
5 minutes. The resulting cDNA was stored at −20C for real-time poly-
merase chain reaction (qPCR) using a SensiMix SYBR & Fluorescein kit
(Bioline) according to the manufacturer's instructions. A total of 20 μL
of qPCR sample contained 50 ng/μL cDNA, SenisMix SYBR & Fluores-
cein, 0.25 μM forward primer, and 0.25 μM reversal primer. The
primer sequences used are 50-AGATCTCGCACTCCAT-30 (forward) and
50-CTCCTTCTCACGAGTCC-30 (reverse) for Piezo1, and 50-TTGAGACCT
TCAACACCC-30 (forward) and 50-TCTCTTGCTCGAAGTCC-30 (reverse)
for β-actin. Real-time PCR was performed using a ROTOR-Gene model
6000 machine (Corbett Research), consisting of 95C for 10 minutes,
45 cycles of 95C for 10 seconds, 60C for 15 seconds, and 72C for
20 seconds, followed bymelting test from 72C to 95C. Data were ana-
lyzed using the ROTOR-Gene 6000 series software. The PCR products
with the anticipated size were confirmed by melting curve analysis. The
cycle threshold value (Ct), representing the minimal cycle number at
which the fluorescence signal grows above the background level,71 was
set at 0.2. The mRNA expression level of Piezo1 was normalized to that
of β-actin based on the following equation72: 2[−(CtPiezo1−Ctβ-actin)]. The
PCR products were also analyzed by electrophoresis on 2% agarose gels,
and gel images were captured with a G:BOX gel imaging system
(Syngene).
2.4 | Immunocytochemistry
Cells were seeded on sterile 13-mm circular glass coverslips placed in
24-well plates at 20 000 cells per well and incubated for 48 hours. Cells
were washed twice with PBS and fixed with 4% paraformaldehyde for
20 minutes. After washed with PBS three times, cells were perme-
abilized by incubation in PBS containing 0.3%TritonX-100 for 5minutes.
Cells werewashed three timeswith PBS and incubated in PBS containing
10% goat serum for 1 hour at room temperature. Cells were incubated
with the primary rabbit anti-Piezo1 antibody (Proteintech) at a dilution
of 1:100 overnight at 4C. After washed with PBS three times, cells
were incubated with the secondary fluorescein isothiocyanate-
conjugated goat anti-rabbit IgG antibody at 1:500 at room tempera-
ture for 1 hour in dark. After washed with PBS and rinsed with water,
cells were mounted on a microscope slide with antifade mounting
medium containing 40 ,6-diamidino-2-phenylindole (DAPI) (Invitrogen).
Fluorescent images were captured using a LMS880 confocal micro-
scope and the ZEN software (Zeiss) or an EVOS Cell Imaging System
(Thermo Fisher Scientific, Waltham, MA, USA).
2.5 | Measurements of intracellular Ca2+
concentration
The intracellular Ca2+ concentration ([Ca2+]i) was monitored using Fura-
2/AM and a Flex-Station III microplate reader (Molecular Devices) as
described in our previous study.40 Cells were seeded at 40 000 cells per
well in 96-well microplates (SARSTEDT) and incubated for 24 hours. Cells
were washed with Ca2+-containing standard buffer solution (SBS in mM:
NaCl 134, KCl 5, CaCl2 1.5,MgCl2 1.2, HEPES 2.38 and glucose 8, pH7.4)
and incubated with SBS containing 4 μM Fura-2/AM and 0.04% pluronic
acid F-127 at 37C for 45 minutes in dark. Cells were washed with SBS
twice and incubated for 30 minutes with 160 μL of Ca2+-containing
or Ca2+-free SBS (in mM: NaCl 134, KCl 5, MgCl2 1.2, HEPES 2.38, glu-
cose 8 and EGTA 0.4, pH 7.4) to investigate Yoda1-induced change in the
[Ca2+]i. After the basal line was established for 30-60 seconds, 40 μL of
SBS containing Yoda1 at five times of the indicated final concentrations
was transferred into each well from the compound plate into the cell
plate. In the experiments studying the effects of RR or GsMTx4 on
Yoda1-induced increase in the [Ca2+]i, cells were treated with RR for
5 minutes during the recording or with GsMTx4 30 minutes prior to and
during the recording. The ratio of fluorescence intensity, excited at
340 and 380 nm, respectively, and emitted at 510 nm (F340/F380), was
used to indicate the [Ca2+]i. Data analysis was carried out using Origin.
Themean data are presented by expressing the F340/F380 as a percentage
of the F340/F380 from cells under the control conditions.
2.6 | Transfection with siRNA
Cells were seeded in 96-well microplates or 24-well plates at 40 000
cells per well for measurement of the [Ca2+]i andmigration assay, respec-
tively, and in 6-well plates at 80000 cells per well for RT-qPCR. After
24 hours, cells were transfected with 30-50 nM of Piezo1-specific
siRNA (siPiezo1) and control siRNA (siCTL) (control siRNA1#; Ambion or
Dharmacon), using Lipofectamine RNAiMAX transfection reagent
(Invitrogen) according to themanufacturer's instructions. Cellswere used
for measurement of the [Ca2+]i and migration assays 48 hours and for
RT-qPCR 72 hours posttransfection. The difference in the Piezo1mRNA
expression in cells transfectedwith siPiezo1 relative to that in cells trans-
fected with siCTL was calculated using the 2-ΔΔCt method, where
ΔΔCt = [(CtPiezo1−Ctβ-actin)siPiezo1− (CtPiezo1−Ctβ-actin)siCTL].72
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2.7 | Cell migration assay
Cell migration was determined using the wound healing assay as
described in our previous study,40 and the wound area was created
using a two-chamber insert (Ibidi) placed in the middle of each well of
24-well plates. Cells were seeded at 20 000-25 000 cells per chamber
and incubated for 16-17 hours. The insert was lifted carefully, and
cells were gently rinsed with PBS. Fresh culture media supplemented
with 2% FBS with or without containing Yoda1 were added into each
well. In experiments examining the effects of inhibitors (apyrase,
PPADS, PF431396, and U0126) on cell migration, cells were
pretreated with the inhibitor at the indicated concentrations for
30 minutes and the inhibitor continued to be present during the
whole essay. Phase contrast images were captured using an EVOS
Cell Imaging System at 0, 24, 48, and 72 hours. The wound area was
calculated using the TScratch software. For individual experiments,
wound healing was derived by the difference between the initial
wound area and the ones at 24, 48, or 72 hours and expressed as per-
centage of the initial wound area (eg, Figure 3B-E). To mitigate the
variations between different experiments, the mean would healing
F IGURE 1 Expression of the Ca2+-permeable Piezo1 channel on hDP-MSC. A, Representative agarose gel images showing positive detection
by RT-PCR of Piezo1 mRNA expression in hDP-MSC cells from each of the four donors examined (9F, 20M, 22M, and 32F). Similar results were
observed in at least two independent experiments. The solid and hollow arrowheads on the right indicate the PCR products for β-actin and
Piezo1, respectively. B, Representative immunofluorescent images showing staining of cells from each of the four donors with the anti-Piezo1
antibody (top) or only with the second antibody (bottom). Scale bar = 20 μm. C,D, Representative intracellular Ca2+ responses in Ca2+-containing
solution (+Ca2+) to 0.1 (black), 0.3 (red), 1 (blue), 3 (magenta), and 10 μM (green) Yoda1 (left) and mean peak Ca2+ responses (right) from one set of
experiments using four wells of cells for each concentration, in cells from 9F (C) and 22M (D). E-H, Representative Ca2+ responses to 3 μM Yoda1
in Ca2+-containing (+Ca2+) or Ca2+-free (-Ca2+) solutions in parallel experiments (left) and mean peak Ca2+ responses (right) from one set of
experiment using four wells of cells for each condition, in cells from 9F (E), 20M (F), 22M (G), and 32F (H). **P < .01 and ***P < .001
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was presented by expressing the wound healing as percentage of that
under control condition at the same time points (eg, Figure 3F).
2.8 | Measurement of ATP release
ATP release was determined using a StayBrite Highly Stable ATP Bio-
luminescence Assay kit (BioVision) to measure the ATP concentration
in the culture medium according to the manufacturer's instructions.
Cells were plated at 50 000-60 000 cells/well in 200 μL of standard
culture medium in a 96-well plate and incubated overnight. Next day,
cells were subjected to starvation by replacing the culture medium
with fresh media without FBS and incubating for 2 hours. Cells were
treated with 100 μM suramin for 30 minutes at 37C in order to pre-
vent ATP hydrolysis, as described in a previous study.38 After cells
were exposed to 1 μM Yoda1 for 30 minutes at 37C, the culture
medium were collected, placed in 1.5-mL Eppendorf tubes on ice, and
centrifuged at 11 000g for 5 minutes at 4C. The supernatants were
transferred to a 96-well plate with 10 μL per well in triplicate for each
condition. The luminescence intensity was measured using a Flex-
Station III microplate reader. The ATP concentration was derived
using a standard curve constructed using 10, 30, 100, 1000, and
10 000 nM ATP.
2.9 | Data presentation and statistical analysis
All data are presented as mean ± SEM, where appropriate. Statistical
analysis was performed using Origin; Student's t test was used for
comparison between two groups, and one-way ANOVA followed by
Fisher's test for comparison of multiple groups, with P < .05 being sta-
tistically significant.
F IGURE 2 Pharmacological and genetic inhibition of Yoda1-induced Piezo1-mediated intracellular Ca2+ responses in hDP-MSC. A-
C, Yoda1-induced Ca2+ responses (9F) and peak Ca2+ responses (9F, 20M, and 32F) in control cells and cells treated with ruthenium red (RR) for
5 minutes from one set of experiments using 3-4 wells of cells for each condition. D, Summary of Yoda1-induced peak Ca2+ responses in RR-
treated cells from 9F, 20M, and 32F, as percentage of that in control cells, from three independent experiments. E,F, Yoda1-induced Ca2+
responses (9F) and peak Ca2+ responses (9F and 20M) in control and cell prior treated with GsMTx4 for 30 minutes from one set of experiments
using 3-4 wells of cells for each condition. G, Summary of Yoda1-induced peak Ca2+ responses in GsMTx4-treated cells as percentage of that
in control cells from four independent experiments using cells from 9F and 20M. H, Summary of Piezo1/β-actin in cells transfected with
siCTL or siPiezo1 as percentage of that in siCTL-transfected cells from eight independent experiments using cells from 9F, 20M, and 32F. I-
K, Yoda1-induced Ca2+ responses in cells transfected with siCTL or siPiezo1 from 9F (I), 20M (J), and 32F (K) from one set of experiments using
four wells of cells for each condition. Cells were exposed to 5 μM ionomycin at the end of recordings (J, K). L, Summary of peak Yoda1-induced
Ca2+ responses in siPiezo1-transfected cells as percentage of that in siCTL-transfected cells from five independent experiments using from 9F,
20M, and 32F, *P < .05; **P < .01; and ***P < .001
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3 | RESULTS
3.1 | The Ca2+-permeable piezo1 channel is
expressed in hDP-MSCs
We began with using RT-qPCR to analyze the Piezo1 expression. The
Piezo1 mRNA was readily detected in hDP-MSCs from all four donors,
albeit with some variations in themRNA level among the different donors
(Figure 1A and Supplementary Figure S1). Consistently, as observed in
cells from all the donors, there were positive and also variable immunore-
activities in cells labeled with the anti-Piezo1 antibody but not in cells
labeled only with the secondary antibody (Figure 1B). We next examined
the functional expression of the Piezo1 channel in hDP-MSCs by moni-
toring intracellular Ca2+ responses to Yoda1, the Piezo1 channel-specific
activator.73 In extracellular Ca2+-containing solution, brief exposure to
Yoda1 (0.1-10 μM) induced concentration-dependent Ca2+ responses
with ≥1 μM Yoda1 inducing a significant increase in the [Ca2+]i in cells
from two donors examined (Figure 1C,D). In hDP-MSCs from all four
donors, brief exposure to 3 μM Yoda1 consistently evoked robust
increases in the [Ca2+]i in extracellular Ca
2+-containing solution and, by
contrast, no or very little change in the [Ca2+]i in extracellular Ca
2+-free
solution (Figure 1E-H), indicating that Yoda1 almost exclusively induced
extracellular Ca2+ influx. Next, we determined the effects of RR, which is
known to inhibit the Piezo1 channel with a potency of ~5 μM,43 and
F IGURE 3 Yoda1-induced activation of the Piezo1 channel stimulates hDP-MSCmigration. A, Representative images showing thewound areas at
0, 24, 48, and72 hours, using cells from9F in the absence (CTL) and presence of indicated concentrations of Yoda1 in the culturemedium. Scale
bar = 500 μm. B-E,Wound healing indicated by the reduction in thewound areas as percentage of thewound area at 0 hour using cells from9F (B, as shown
inA), 20M (C), 22M (D), and 32F (E). F, Summary of themeanwound healing as percentage of that under control conditions at the same time points in parallel
experiments fromeight independent experiments using all four donors shown inA-E. G, Summary ofmeanwound healing under indicated conditions, from
five independent experiments using cells from9F and 32F thatwere transfectedwith control siRNA (siCTL) and Piezo1-specific siRNA (siPiezo1). *P < .05
compared to control condition at the same time points. #P < .05 and ##P < .001 compared to cells transfectedwith siCTL and exposed to Yoda1
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GsMTx4, a peptide from tarantula venom that inhibits the Piezo1 channel
in the low μM concentrations,74 on Yoda1-induced Ca2+ responses.
Treatment with 10 or 30 μM RR for 5 minutes exerted no effect on the
basal Ca2+ level but strongly and concentration-dependently reduced
Yoda1-induced increase in the [Ca2+]i in cells from three donors examined
(Figure 2A-D and Supplementary Figure S2). Treatment with 0.3, 1 or
3 μMGsMTx4 for 30 minutes also resulted in a concentration-dependent
inhibition of Yoda1-induced increase in the [Ca2+]i in cells from two
donors examined (Figure 2E-G and Supplementary Figure S3). Finally, we
examined the effect of siRNA-mediated knockdown of the Piezo1
expression on Yoda1-induced Ca2+ responses. Genetic depletion of the
Piezo1 expression (Figure 2H) strongly suppressed Yoda1-induced
increase in the [Ca2+]i in cells from three donors tested (Figure 2I-L
and Supplementary Figure S4). Taken together, these results provide
pharmacological and genetic evidence that consistently supports the
expression of the Piezo1 channel in hDP-MSCs.
3.2 | Activation of the Piezo1 channel stimulates
hDP-MSC migration
To test whether the Piezo1 channel plays a role in regulating hDP-MSC
migration, as recently reported in endothelial cell56 and various cancer
cells,50,57-59 we used the wound healing assay to examine the effect of
Yoda1 on cell migration (Figure 3). Inclusion of 0.1-1 μM Yoda1 in the
culture medium resulted in a concentration-dependent increase in
cell migration, with 0.3 and 1 μM Yoda1 significantly accelerating cell
migration at 24, 48, and 72 hours, and such stimulation was observed in
F IGURE 4 The PYK2 and
MEK/ERK signaling pathways are
critical for Yoda1-induced
stimulation of hDP-MSC
migration. A-C, Wound healing
for cells from 9F (A), 20M (B), and
32F (C) under control condition
(CTL) and cells exposed to 0.3 μM
Yoda1 alone (Yoda1) or together
with 10 nM PF431396 (PF
+ Yoda1). D, Summary of mean
wound healing in three
independent experiments for cells
from 9F, 20M, and 32F under
control condition (CTL) and cells
exposed to Yoda1 alone or
together with PF as shown in A-
C. E-G, Wound healing for cells
from 9F (E), 20M (F), and 32F
(G) under CTL and cells exposed
to 0.3 μM Yoda1 alone (Yoda1) or
together with 1 μM U0126
(U0126 + Yoda1). H, Summary of
mean wound healing in three
independent experiments for cells
from 9F, 20M, and 32F under
control condition (CTL) and cells
exposed to Yoda1 alone or
together with U0126 as shown in
E-G. *P < .05 compared to control
condition at the same time points,
and #P < .05 and ##P < .001
compared to cells exposed to
Yoda1
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hDP-MSCs from all four donors, with some variations among the differ-
ent donors (Figure 3A-F). Prolonged exposure to Yoda1 at 3 μMand par-
ticularly 10 μM for 24-72 hours was detrimental to hDP-MSCs (data not
shown). Unfortunately, prolonged exposure to RR or GsMTx4 was also
cytotoxic, preventing from pharmacologically interrogating the role of
the Pieoz1 channel inmediating Yoda1-induced stimulation of cell migra-
tion. We therefore turned to examine the effect of siRNA-mediated
knockdown of the Piezo1 expression on cell migration. Yoda1-induced
F IGURE 5 Yoda1-induced stimulation of
hDP-MSC migration depends ATP release and
activation of P2 purinergic signaling. A, The ATP
concentrations in the medium culturing cells
under control condition (CTL) or treated with
100 μM suramin (CTRL+Sur) or with 100 μM
suramin and 1 μM Yoda1 (Yoda1 + Sur). The
results were obtained in triplicates. **P < .01.
B, Summary of mean wound healing from three
independent experiments for cells from 9F under
control condition (CTL) and cells exposed to
0.3 μM Yoda alone (Yoda1) or together with 0.3 or
1 U/mL apyrase (Apy + Yoda1). C, Summary of
mean wound healing in three independent
experiments for cells from 9F under CTL and cells
exposed to 0.3 μM Yoda1 alone (Yoda1) or
together with 30 μM PPADS (PPAD+Yoda1).
*P < .05 compared to control condition at the
same time points and #P < .05 compared to cells
exposed to Yoda1 alone
F IGURE 6 The PYK2 and MEK/ERK signaling pathways are critical for ATP-induced stimulation of hDP-MSC migration. A, Representative
wound healing in cells from 9F under control (CTL) or cells exposed to 30 μM ATP, indicated by the reduction in the wound area expressed as
percentage of the wound area at 0 hour. B, Summary of mean wound healing as percentage of that under CTL at the same time points in parallel
experiments, from 10 independent experiments using cells from 9F and 22M. C,D, Summary of mean wound healing in three independent
experiments for cells from 9F under CTL and cells exposed to 30 μM ATP alone (ATP) or together with 10 nM of PF431396 (PF + ATP, C) or
1 μM U0126 (U0126 + ATP, D). *P < .05 and **P < .001 compared to control condition at the same time points, and #P < .05 and ##P < .001
compared to cells exposed to ATP alone (C and D)
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stimulation of cell migration was sustained in cells transfected with con-
trol siRNA but lost in cells transfected with Piezo1-specific siRNA, which
was consistently observed in cells from two donors tested (Figure 3G).
These results support that activation of the Piezo1 channel stimulates
hDP-MSCmigration.
3.3 | PYK2 and MEK/ERK are engaged in
Yoda1-induced stimulation of hDP-MSC migration
As introduced above, wewere interested in examining whether the PYK2
and MEK/ERK signaling pathways participate in Piezo1-dependent regu-
lation of hDP-MSCmigration. In hDP-MSCs from three donors examined,
treatment with 10 nM PF431396, a PYK2 inhibitor, prior to and during
exposure to Yoda1, strongly inhibited Yoda1-induced stimulation of cell
migration (Figure 4A-D). Similarly, treatment with 1 μM U0126, a
MEK/ERK inhibitor, resulted in strong inhibition of Yoda1-induced stimu-
lation of cell migration (Figure 4E-H). These results provide clear evidence
to suggest that the PYK2 and MEK/ERK signaling pathways are critically
engaged in Piezo1-dependent regulation of hDP-MSCmigration.
3.4 | Yoda1-induced hDP-MSC migration depends
on ATP release and P2 receptor activation
Next, we examined the hypothesis that activation of the Piezo1 channel
stimulates hDP-MSC migration via inducing ATP release and subsequent
activation of the P2 receptor purinergic signaling. We examined
Yoda1-induced ATP release from hDP-MSCs (Figure 5A). Inclusion of
100 μM suramin in the culture medium to prevent ATP hydrolysis38
resulted in slight but statistically insignificant elevation in the ATP concen-
tration, consistent with a previous study suggesting a low level of ATP
release under the normal culturing conditions. 36 Exposure to 1 μMYoda1
for 30 minutes resulted in a 5.5-fold increase in the ATP concentration
(Figure 5A), indicating that activation of the Piezo1 channel induces ATP
release. We moved on to determine the effect of treatment with apyrase,
an ATP-scavenging enzyme, on Yoda1-induced increase in hDP-MSC
migration. Inclusion of 1 U/mL apyrase in the culture medium completely
prevented Yoda1-induced stimulation of cell migration. Treatment with
0.3U/mL apyrase also significantly reducedYoda1-induced increase in cell
migration at 24 hours but became less effective at 48 hours or ineffective
at 72 hours (Figure 5B). Importantly, treatment with apyrase alone was
without significant effect on cell migration (Supplementary Figure S5A).
These results indicate that ATP release mediates Yoda1-induced stimula-
tion of hDP-MSC migration. Our previous study showed that treatment
with 30 μM PPADS, a generic P2 receptor antagonist, prior to and during
exposure to ATP, effectively prevented ATP-induced stimulation of hDP-
MSC migration.40 Treatment with 30 μM PPADS also resulted in strong
inhibition of Yoda1-induced stimulation of cell migration (Figure 5C).
Again, treatment with PPADS alone had no effect on cell migration
(Supplementary Figure S5B). Taken together, these results provide consis-
tent evidence to show that activation of the Piezo1 channel stimulates
hDP-MSCmigration via inducing ATP release and P2 receptor activation.
If the above-described notion is correct, we anticipate that activation
of the PKY2 and MEK/ERK signaling pathways are also critical in ATP-
induced stimulation of hDP-MSCmigration. Exposure to 30 μMATP stim-
ulated cell migration in hDP-MSCs from two donors used (Figure 6A,B), as
reported in our previous study.40 Indeed, ATP-induced stimulation of cell
migration was prevented by treatment with PF431396 or U0126
(Figure 6C,D), as shown above for Yoda1 (Figure 4). These results have
extended our previous finding40 to show engagement of the PYK2 and
MEK/ERK signaling pathways in ATP-induced stimulation of hDP-MSC
migration. Such results are highly consistent with the notion that activa-
tion of the Piezo1 channel stimulates hDP-MSC migration via inducing
ATP release and subsequent activation of the P2 receptor purinergic sig-
naling and downstreamPYK2 andMEK/ERK signaling pathways.
4 | DISCUSSION
We in this study showed the expression of the Piezo1 channel in
hDP-MSCs as a previously unrecognized mechanism regulating human
MSC migration. We provide further evidence to suggest that activa-
tion of the Piezo1 channel regulates cell migration via inducing ATP
release and subsequent activation of the P2 receptor purinergic sig-
naling and downstream PYK2 and MEK/ERK signaling pathways
(Figure 7). These novel findings provide a better understanding of the
mechanisms mediating ATP release from MSCs and regulation of
MSC migration. Such information is useful in developing strategies to
improve MSC homing and applications of MSCs in regenerative medi-
cine and tissue engineering.
F IGURE 7 Schematic summary of proposed signaling mechanisms
for Piezo1-dependent ATP release from hDP-MSC and regulation of
cell migration. Activation of the Piezo1 channel induces ATP release.
ATP activates the P2 receptors and induces activation of the proline-
rich tyrosine kinase 2 (PYK2) and the mitogen-activated protein
kinase/extracellular signal-regulated kinase (MEK/ERK), which may
act as upstream and downstream signaling pathways (as depicted
here) or independent signaling pathways, leading to an increase in cell
migration. The activators and inhibitors used in this study to target
various signaling molecules are highlighted in green and red,
respectively
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Our study provides independent lines of evidence to demonstrate
the expression of the Piezo1 channel in hDP-MSCs. The Piezo1 mRNA
and protein were detected in all the cell preparations from four donors,
albeit with some noticeable variations among the different donors
(Figure 1A,B and Supplementary Figure S1). Consistently, brief expo-
sure to Yoda1 induced Ca2+ influx-dependent increases in the [Ca2+]i in
hDP-MSCs from all the donors (Figure 1C-H). Moreover, as shown in
cells from multiple donors, Yoda1-induced Ca2+ responses were
inhibited by RR and GsMTx4, and also by siRNA-mediated knockdown
of the Piezo1 expression (Figure 2 and Supplementary Figures S2-S4).
These results provide strong evidence to show the expression of the
Piezo1 channel in hDP-MSCs. Our study, together with a recent study
examining hBM-MSCs,60 supports the expression of the Piezo1 chan-
nel in human MSCs of different tissues. Yoda1-induced increase in the
[Ca2+]i in hDP-MSCs was abolished by removing extracellular Ca
2+
(Figure 1E-H), suggesting that the Piezo1 channel is located in the
plasmamembrane, as described in many other types of cells.43,44,54
Recent studies have reported a role for the Piezo1 channel in regu-
lating cell migration in endothelial cell56 and cancer cells.50,57-59 In this
study, we provide evidence to show that the Piezo1 channel plays a simi-
lar role in hDP-MSCs. Persistent exposure to Yoda1 stimulated hDP-
MSCmigration, and such stimulatory effect was consistently observed in
cells from all the four donors (Figure 3A-F). Unfortunately, prolonged
treatment with RR or GsMTx4 caused cytotoxicity to hDP-MSCs, thus
preventing from using them as pharmacological means to examine the
role of the Piezo1 channel in Yoda1-induced stimulation of cell migra-
tion. Nonetheless, we showed that siRNA-mediated knockdown of the
Piezo1 expression strongly inhibited Yoda1-induced stimulation of cell
migration (Figure 3G), supporting a significant role for the Piezo1 channel
in regulating hDP-MSCmigration.
In this study, we have gained further insights into Piezo1-dependent
regulation of hDP-MSC migration. Recent studies support a critical role
for the Piezo1 channel, upon mechanical or chemical activation, in induc-
ing ATP release from urothelial cell,54 red blood cell,55 and endothelial
cell.48 Here, we showed that activation of the Piezo1 channel with Yoda1
induced substantial ATP release from hDP-MSCs (Figure 5A). Moreover,
Yoda1 became ineffective in stimulating cell migration in the presence of
apyrase, a potent ATP scavenger (Figure 5B), indicating that ATP release
mediates Piezo1-dependent regulation of cell migration. These findings
are nicely aligned with our previous study showing that application of
ATP stimulates hDP-MSC migration under the same experimental
conditions,40 which we have confirmed in this study (Figure 6A,B). We
further showed that Yoda1-induced Piezo1-dependent stimulation of
hDP-MSC migration was strongly inhibited by PPADS (Figure 5B). Taken
together, these results strongly support that activation of the Piezo1
channel stimulates hDP-MSCmigration via inducing ATP release and sub-
sequent activation of the P2 receptor purinergic signaling. Our previous
study identified P2X7, P2Y1, and P2Y11 as the major P2 receptors that
mediate ATP-induced increase in hDP-MSC migration.40 It is anticipated
that these P2 receptors are engaged in Piezo1-dependent stimulation of
hDP-MSCmigration but the supporting evidence is required.
In this study, we have also shed light on the downstream signaling
pathways in Piezo1-dependent stimulation of hDP-MSCmigration as well
as ATP-induced P2 receptor-dependent stimulation of hDP-MSC migra-
tion reported in our previous study.40 PYK2 is a well-recognized signaling
mechanism transducing Ca2+-dependent induction of the MEK/ERK sig-
naling pathway.64,66,67,69,70 Our results from hDP-MSCs from three
donors showed that Yoda1-induced cell migration was prevented by
inhibiting PYK2 (Figure 4A-D) and MEK/ERK (Figure 4E-H). These results
strongly suggest that the PYK2 andMEK/ERK signaling pathways are criti-
cally engaged in Piezo1-dependent stimulation of cell migration. Our find-
ing is also consistent with a recent study proposing a role for the Piezo1
channel in rat DP-MSCs in mediating ultrasound-induced activation of the
MEK/ERK signaling pathway.61 ATP-induced P2 receptor-dependent
stimulation of hDP-MSCmigration was also prevented by inhibiting PYK2
and MEK/ERK (Figure 6C,D). Such findings are interesting as they are
clearly consistent with the idea that activation of the Piezo1 channel stim-
ulates cell migration via inducing ATP release and subsequent activation of
the P2 receptor purinergic signaling and downstreamPYK2 andMEK/ERK
signaling pathways (Figure 7). There is evidence that mechanical stimulus-
induced increase in the [Ca2+]i in MSCs and other cell types depends on
release of ATP and subsequent activation of the P2 receptor purinergic
signaling.35,75 It is interesting to establish whether mechanical activation
of the Peizo1 channel can induce ATP release and regulate hDP-MSC
migration, as we have shown here for chemical activation of the Pieoz1
channel. Moreover, both ATP-induced activation of the P2 purinergic sig-
naling reported in our previous study40 and activation of the Piezo1 chan-
nel as shown in the present study can elevate the [Ca2+]i. Further
investigations are required to better understand how theCa2+ signals from
these two distinctivemechanisms regulate hDP-MSCmigration.
5 | CONCLUSION
In conclusion, we show that activation of the Piezo1 channel as a
novel mechanism to stimulate in MSC migration via inducing ATP
release and subsequent activation of the P2 receptor purinergic sig-
naling and downstream PYK2 and MEK/ERK signaling pathways. Such
novel insights into the molecular and signaling mechanisms in the reg-
ulation of MSC migration should be useful for a better understanding
of the MSC biology and translational use of MSCs in regenerative
medicine and tissue engineering.
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